Approval · Notice of Compliance 35677 · 2025
RYBREVANT: Notice of Compliance 35677
Issued July 16, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 35677
- Date
- July 16, 2025
- Company
- Janssen Inc.Toronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- A Addition of a manufacturing facility for the drug substance
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RYBREVANT | Not yet assigned | — |
Medicinal ingredients
- AMIVANTAMAB 350 MG per 7ML